London, UK and Cambridge, UK, 20th October 2015 / Domainex Ltd. and Imperial College London today announce a new partnership focused on the discovery of novel therapies to treat myocardial infarction, also known as a heart attack.
20th October 2015
7th October 2015
Domainex Ltd. is pleased to announce that it is enlisting the support of Shin Kitaoka of BioGemini Ltd. to provide advice on expansion into the Japanese market
15th September 2015
Domainex and Auspherix today announce an expansion of their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The programme has been extended through to 2017.
3rd September 2015
Current Challenges, Novel Tools and Emerging Targets with Trevor Perrior, Ph.D., Director, Research, Domainex Limited Gregg Siegal, Ph.D., CEO, ZoBio
1st July 2015
Domainex Ltd, a private drug discovery service company, today announces that it is launching an integrated bioassay service platform, BioassayBuilder.
11th May 2015
Domainex announces the grant of US and European patents for its lead programme, targeting IKK-epsilon and TBK1 for the treatment of COPD and Psoriasis.
20th April 2015
20th April 2015, Belfast and Cambridge, UK: Dr Dan Longley’s research team at Queen’s University Belfast, and Domainex Ltd., specialists in drug discovery solutions and
8th April 2015
Barry Knight is a Chartered Accountant and brings extensive financial expertise to Domainex, having been an executive director for Life Sciences companies for more than 25 years. Barry was previously Finance Director of both Trigen Holdings plc and AIM-listed Fulcrum Pharma plc.
26th February 2015
Domainex spoke with PharmaTelevision in December 2014 to explain the collaboration with ZoBio and the combination of Domainex's CDH technology with ZoBio's state-of-the-art NMR capabilities; Domainex's work on behalf of Auspherix and Domainex's future strategicplanning
8th December 2014
ZoBio and Domainex Ltd. announce a collaboration with FORMA Therapeutics to provide NMR-based structural biology services for a substantial panel of FORMA drug targets.